1. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
- Author
-
Amanda Kofides, Kirsten Meid, Sara J. Buhrlage, Jinhua Wang, Manit Munshi, Jorge J. Castillo, Jiaji G. Chen, Kenneth C. Anderson, Michael D. Cameron, Guang Yang, Maria Luisa Guerrera, Xia Liu, Lian Xu, Nicholas Tsakmaklis, Nikhil C. Munshi, Jianwei Che, Li Tan, Maria Demos, Nathanael S. Gray, Christopher J. Patterson, Steven P. Treon, and Zachary R. Hunter
- Subjects
Proto-Oncogene Proteins c-hck ,Lymphoma ,Immunology ,Antineoplastic Agents ,Mice, SCID ,Biochemistry ,chemistry.chemical_compound ,Piperidines ,Pharmacokinetics ,Mice, Inbred NOD ,Cell Line, Tumor ,hemic and lymphatic diseases ,Agammaglobulinaemia Tyrosine Kinase ,Tumor Cells, Cultured ,medicine ,Animals ,Humans ,Bruton's tyrosine kinase ,Protein Kinase Inhibitors ,Lymphoid Neoplasia ,biology ,Venetoclax ,business.industry ,Adenine ,Waldenstrom macroglobulinemia ,Cell Biology ,Hematology ,medicine.disease ,In vitro ,chemistry ,Drug Resistance, Neoplasm ,Ibrutinib ,Mutation ,Myeloid Differentiation Factor 88 ,biology.protein ,Cancer research ,Female ,business - Abstract
Activating mutations in MYD88 promote malignant cell growth and survival through hematopoietic cell kinase (HCK)–mediated activation of Bruton tyrosine kinase (BTK). Ibrutinib binds to BTKCys481 and is active in B-cell malignancies driven by mutated MYD88. Mutations in BTKCys481, particularly BTKCys481Ser, are common in patients with acquired ibrutinib resistance. We therefore performed an extensive medicinal chemistry campaign and identified KIN-8194 as a novel dual inhibitor of HCK and BTK. KIN-8194 showed potent and selective in vitro killing of MYD88-mutated lymphoma cells, including ibrutinib-resistant BTKCys481Ser-expressing cells. KIN-8194 demonstrated excellent bioavailability and pharmacokinetic parameters, with good tolerance in rodent models at pharmacologically achievable and active doses. Pharmacodynamic studies showed sustained inhibition of HCK and BTK for 24 hours after single oral administration of KIN-8194 in an MYD88-mutated TMD-8 activated B-cell diffuse large B-cell lymphoma (ABC DLBCL) and BCWM.1 Waldenström macroglobulinemia (WM) xenografted mice with wild-type BTK (BTKWT)– or BTKCys481Ser-expressing tumors. KIN-8194 showed superior survival benefit over ibrutinib in both BTKWT- and BTKCys481Ser-expressing TMD-8 DLBCL xenografted mice, including sustained complete responses of >12 weeks off treatment in mice with BTKWT-expressing TMD-8 tumors. The BCL_2 inhibitor venetoclax enhanced the antitumor activity of KIN-8194 in BTKWT- and BTKCys481Ser-expressing MYD88-mutated lymphoma cells and markedly reduced tumor growth and prolonged survival in mice with BTKCys481Ser-expressing TMD-8 tumors treated with both drugs. The findings highlight the feasibility of targeting HCK, a key driver of mutated MYD88 pro-survival signaling, and provide a framework for the advancement of KIN-8194 for human studies in B-cell malignancies driven by HCK and BTK.
- Published
- 2021
- Full Text
- View/download PDF